The DOI matches its Crossref record; the references it cites are not checked yet.
DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients
Open accessAbstract
Context: A substantial proportion of athyreotic levothyroxine (LT4)-treated patients experience hypothyroid-like symptoms. During LT4 replacement, levels of the active hormone triiodothyronine (T3) strictly depend on type 2-deiodinase (D2)-mediated activation of LT4. The Thr92Ala polymorphism and the 258 G/A in the DIO2 gene have been associated with various clinical conditions. Objectives: To investigate the effects of DIO2 polymorphisms in thyroid hormone homeostasis. Design: We compared the presurgical hormonal status of thyroidectomized LT4-treated patients who had a similar thyroid-stimulating hormone (TSH) level with their postsurgery status and analyzed their DIO2 genotype in a subgroup of 102/140 (72.8%) of patients. We measured the enzymatic properties of Thr92Ala in living cells and in relevant generated mouse models. Subjects and methods: A total of 140 thyroidectomized subjects were included. Serum free T3 (FT3), free thyroxine, and TSH levels were directly measured. Immunohistochemistry and immunoblotting were performed for D2 protein. Results: The DIO2 genotyping revealed an association between low FT3 values and Thr92Ala. Specifically, the mean postsurgery FT3 levels were significantly lower in patients carrying the mutated allele(s) than in wild-type patients, in whom FT3 postsurgical levels were similar to presurgery levels. The −258 G/A variation was not associated with hormonal alteration. We found that endogenous wild-type D2 and Thr92Ala share the same subcellular localization but differ in protein stability. Importantly, Thr92Ala reduced D2-mediated thyroxine to T3 conversion. Conclusions: Thyroidectomized patients carrying Thr92Ala are at increased risk of reduced intracellular and serum T3 concentrations that are not adequately compensated for by LT4, thus providing evidence in favor of customized treatment of hypothyroidism in athyreotic patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Transfection studies in cultures of mouse pituitary cells from DIO2-null mice resulted in less TSH suppression in cells expressing the DIO2 Ala/Ala homozygote, as compared with cells expressing wild type Thr92-DIO2 (19).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [19]
In the citing paper
“Notably, an Italian study with a relatively small number of participants revealed that LT4-treated thyroidectomized carriers of at least one Thr92Ala-DIO2 allele exhibited lower serum T3 levels, despite a normal serum TSH (19).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [19]
In the citing paper
“Thus, while endocrinologists traditionally rely on TSH levels and TSH “normalization” during L-T4 therapy to reflect euthyroidism in all tissues, these deiodinase polymorphism studies shed some doubt on the validity of this practice for all patients in view of some clinical evidence supporting a role for combination T4/T3 treatment.”
From Can Reverse T3 Assay Be Employed to Guide T4 vs. T4/T3 Therapy in Hypothyroidism? (2019) · cites this paper as [16]
In the citing paper
“One common Thr92Ala polymorphism has been associated with insulin resistance, obesity, hypertension and importantly, altered responses to T4 replacement therapy that predicted the need for a higher T4 dosage, although only in thyroidectomized subjects but not in patients with autoimmune hypothyroidism (14–16).”
From Can Reverse T3 Assay Be Employed to Guide T4 vs. T4/T3 Therapy in Hypothyroidism? (2019) · cites this paper as [16]
In the citing paper
“Later, this polymorphism was found to be associated with an approximately 40% reduction in the catalytic activity of D2 (28, 29), and a mouse carrying the DIO2 polymorphism exhibited signs of reduced T3 signaling in the brain that responded to therapy containing LT4+LT3 (28).”
From Emerging Therapies in Hypothyroidism (2024) · cites this paper as [29]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 26 · Cited by 151
Metadata
- Authors
- Castagna, M. G., Dentice, M., Cantara, S., Ambrosio, R., Maino, F., Porcelli, T., Marzocchi, C., Garbi, C., Pacini, F., & Salvatore, D.
- Affiliations
- University of Siena (IT)
- University of Naples Federico II (IT)
- Istituto Di Ricovero e Cura a Carattere Scientifico SDN, 80143 Naples, Italy
- CEINGE Biotecnologie Avanzate Franco Salvatore (Italy) (IT)
- Corresponding author
- Salvatore, Domenico
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2017-02-02
- Volume
- 102
- Issue
- 5
- Pages
- 1623-1630
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2611024120
- Cited by
- 151
- References
- 26
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 17 · 2023: 24 · 2022: 18 · 2021: 17 · 2020: 13 · 2019: 17 · 2018: 14 · 2017: 6
- FWCI
- 10.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- DIO2, type 2 deiodinase, triiodothyronine, free T3, levothyroxine, thyroidectomy, hypothyroidism, thyroid hormone homeostasis, protein stability
- MeSH terms
- Iodothyronine Deiodinase Type II, Adolescent, Adult, Aged, Aged, 80 and over, Female, Genotype, Humans, Hypothyroidism, Iodide Peroxidase, Male, Middle Aged, Polymorphism, Genetic, Thyroidectomy, Thyroxine, Triiodothyronine, Polymorphism, Single Nucleotide, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients. https://app.cochat.ai/papers/10.1210/jc.2016-2587
- The paper
- Castagna, M. G., Dentice, M., Cantara, S., Ambrosio, R., Maino, F., Porcelli, T., Marzocchi, C., Garbi, C., Pacini, F., & Salvatore, D. (2017). DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2016-2587
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.